

## TYSABRI Update

### Patients Treated with TYSABRI as of the end of June 2009:

Cumulatively, in the combined clinical trial and post-marketing settings, approximately 61,200 patients have been treated with TYSABRI. Of these, approximately 56,500 patients have been treated in the post-marketing setting.

In the post-marketing setting only and since the reintroduction of TYSABRI in July 2006, approximately

- 30,600 patients have received at least one year of TYSABRI therapy,
- 18,400 patients have received at least 18 months of TYSABRI therapy,
- 10,000 patients have received at least 24 months of TYSABRI therapy.

As of the end of June 2009:

- Approximately 43,300 patients were on TYSABRI therapy worldwide; of these:
- In the U.S., approximately 22,000 patients were on TYSABRI therapy commercially;
- In the rest of world, approximately 20,700 patients were on TYSABRI therapy commercially; and
- In global clinical trials, approximately 600 patients were on TYSABRI therapy.

### Progressive multifocal leukoencephalopathy (PML):

In the period between the reintroduction and approval of TYSABRI in July 2006 and July 24, 2009, the following cases of PML have been confirmed:

Date of PML Confirmation	Duration of TYSABRI Therapy	Treated Indication	Geography
July 24, 2009	29 doses	MS	US
June 23, 2009	30 months	MS	Ex-US
June 19, 2009	34 doses	MS	Ex-US
June 10, 2009	35 doses	MS	Ex-US
May 18, 2009	24 doses	MS	US
April 15, 2009	31 months	MS	Ex-US
February 5, 2009	12 months	MS	Ex-US
December 10, 2008	26 months	MS	Ex-US
October 29, 2008	14 doses	MS	US
July 31, 2008	14 months	MS	Ex-US
July 30, 2008	17 months	MS	Ex-US

### Final TYSABRI Website Update

This TYSABRI Update will be available on the Biogen Idec website until 4:30 PM on Tuesday, July 28, 2009, and is the final posting of this information that will appear on the Biogen Idec website.